WHO advisers recommend Moderna's Bundibugyo shot for trial

On Nov. 4, 2026, WHO Director-General Tedros Adhanom Ghebreyesus said expert groups are recommending that Moderna's mRNA-1469 be added to the Tumaini trial against Bundibugyo virus in the Democratic Republic of the Congo. Moderna said the recommendation followed an Oct. 22 review by WHO's Technical Advisory Group and that the candidate still needs regulatory approval before it joins the study. Moderna also said interim Phase 1 results in healthy adults in Canada showed the shot was generally well tolerated and that a single dose produced binding antibodies, and that CEPI has committed up to $58.5 million for preclinical work, Phase 1 trials, and extra clinical doses.